drugset / Trial / NCT04280965
Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury
Phase 0
Completed
28 enrolled
The University of Texas Health Science Center at San Antonio
South Central MIRECC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A pilot study to evaluate feasibility for a full-scale merit application. Specifically, for veterans considering prolonged exposure (PE) therapy, following the model established by Foa et al, we need to establish safety, and feasibility of quetiapine compared to treatment as usual (TAU) which employs multiple medications commonly used for PTSD in the VA system.
Timeline
- Start
- 2019-02-01
- Primary completion
- 2022-04-29
- Completion
- 2022-10-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quetiapine | Small molecule | 400 mg | — |